Brief: Promis Neurosciences Exceeds Target Enrollment In Precise-Ad Phase 1B Cli Trial
18/12/2025 12:39
Dec 18 (Reuters) - ProMIS Neurosciences Inc PMN.O: PROMIS NEUROSCIENCES EXCEEDS TARGET ENROLLMENT IN PRECISE-AD PHASE 1B CLINICAL TRIAL OF PMN310 IN ALZHEIMER’S DISEASE PROMIS NEUROSCIENCES INC - INTERIM ANALYSIS EXPECTED IN Q2 2026, FINAL RESULTS IN Q4 2026 Source text: ID:nGNX95lDlK Further company coverage: PMN.O ((Reuters.Briefs@thomsonreuters.com;))